Eoin P Flanagan Selected Research

Nervous System Paraneoplastic Syndromes

12/2020	Paraneoplastic Disorders of the Nervous System.
11/2020	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eoin P Flanagan Research Topics

Disease

21	Neoplasms (Cancer) 01/2022 - 08/2011
21	Neuromyelitis Optica (Devic's Disease) 01/2022 - 09/2014
19	Multiple Sclerosis 02/2022 - 01/2015
14	Spinal Cord Diseases 01/2022 - 08/2011
13	Myelitis 12/2021 - 02/2016
10	Optic Neuritis (Retrobulbar Neuritis) 02/2022 - 01/2018
9	Encephalitis (Encephalitis, Rasmussen) 01/2022 - 01/2018
9	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 05/2016
8	Brain Diseases (Brain Disorder) 01/2021 - 04/2011
7	Glioma (Gliomas) 10/2022 - 12/2015
7	Dementia (Dementias) 10/2022 - 10/2010
7	Seizures (Absence Seizure) 01/2021 - 12/2015
5	Autoimmune Diseases of the Nervous System 10/2022 - 01/2018
5	Nervous System Diseases (Neurological Disorders) 12/2021 - 01/2018
5	Epilepsy (Aura) 02/2021 - 01/2017
5	Transverse Myelitis (Necrotizing Myelitis) 01/2021 - 01/2018
5	Sarcoidosis (Schaumann Disease) 12/2020 - 01/2016
4	Leukocytosis (Pleocytosis) 01/2022 - 10/2010
3	Optic Nerve Diseases (Optic Neuropathy) 01/2021 - 10/2018
3	Infarction (Infarctions) 01/2021 - 01/2018
3	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 01/2019 - 01/2016
2	Alzheimer Disease (Alzheimer's Disease) 10/2022 - 06/2014
2	Atrophy 01/2022 - 08/2020
2	Cognitive Dysfunction 01/2022 - 10/2018
2	Ganglion Cysts (Ganglion) 01/2022 - 01/2019
2	Inflammation (Inflammations) 01/2021 - 11/2020
2	Nervous System Paraneoplastic Syndromes 12/2020 - 11/2020
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2020 - 01/2018
2	Optic Atrophy 08/2020 - 01/2018
2	Uveitis 01/2020 - 11/2013
2	Edema (Dropsy) 01/2020 - 01/2018
2	Papilledema 01/2020 - 01/2018
2	Ataxia (Dyssynergia) 11/2019 - 11/2015
2	Lymphoma (Lymphomas) 01/2018 - 11/2012
2	Spondylosis 07/2014 - 05/2013
2	Vasculitis (Vasculitides) 11/2013 - 04/2011
1	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 10/2022
1	Breast Carcinoma In Situ 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Erdheim-Chester Disease 01/2022
1	Infections 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 12/2021
1	Retinal Diseases 06/2021
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 03/2021
1	Hashimoto's encephalitis 01/2021
1	COVID-19 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Granuloma 11/2020
1	Testicular Germ Cell Tumor 11/2020
1	Neurologic Manifestations (Neurological Manifestations) 10/2020
1	Melanoma (Melanoma, Malignant) 10/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2020
1	Hearing Loss (Hearing Impairment) 08/2020

Drug/Important Bio-Agent (IBA)

43	Immunoglobulin G (IgG)IBA 01/2022 - 08/2011
31	Myelin-Oligodendrocyte GlycoproteinIBA 02/2022 - 01/2018
28	AutoantibodiesIBA 10/2022 - 10/2010
22	Biomarkers (Surrogate Marker)IBA 10/2022 - 08/2011
17	AntibodiesIBA 01/2022 - 01/2017
10	Proteins (Proteins, Gene)FDA Link 10/2022 - 10/2010
9	GadoliniumIBA 10/2021 - 05/2013
7	Leucine (L-Leucine)FDA Link 10/2022 - 12/2015
6	Immune Checkpoint InhibitorsIBA 12/2021 - 02/2019
6	AntigensIBA 12/2021 - 08/2011
6	Aquaporin 4IBA 10/2021 - 08/2011
5	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 04/2011
4	Semaphorin-3AIBA 01/2022 - 08/2011
4	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 11/2012
4	Glial Fibrillary Acidic ProteinIBA 09/2019 - 01/2018
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2022 - 02/2017
3	Retinaldehyde (Retinal)IBA 02/2022 - 01/2019
3	Cholinergic ReceptorsIBA 01/2022 - 10/2010
3	Immunosuppressive Agents (Immunosuppressants)IBA 12/2021 - 01/2020
2	Immunoglobulins (Immunoglobulin)IBA 10/2022 - 08/2011
2	amphiphysinIBA 01/2022 - 10/2020
2	ANNA1 antibodyIBA 01/2022 - 01/2018
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 01/2018
2	N-Methylaspartate (NMDA)IBA 01/2021 - 01/2018
2	Oligoclonal BandsIBA 01/2021 - 01/2015
2	N 30IBA 10/2020 - 01/2017
2	Complement System Proteins (Complement)IBA 07/2020 - 01/2020
2	SteroidsIBA 09/2019 - 04/2011
2	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2018 - 10/2010
2	Antiphospholipid AntibodiesIBA 01/2018 - 02/2016
2	Amyloid (Amyloid Fibrils)IBA 06/2014 - 11/2013
1	Cell Adhesion MoleculesIBA 10/2022
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 10/2022
1	pexidartinibIBA 01/2022
1	InterferonsIBA 01/2022
1	Natalizumab (Tysabri)FDA Link 01/2022
1	inebilizumabIBA 01/2022
1	propionic acid (potassium propionate)IBA 01/2022
1	Rituximab (Mabthera)FDA Link 01/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	Antinuclear AntibodiesIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 12/2020

Therapy/Procedure

23	Immunotherapy 01/2022 - 10/2010
5	Therapeutics 01/2021 - 04/2011
1	Plasmapheresis 01/2021
1	Treatment Delay 01/2021